Donor Liver Small Droplet Macrovesicular Steatosis Is Associated With Increased Risk for Recipient Allograft

Won-Tak Choi1, Kuang-Yu Jen, Dongliang Wang

  • 1Departments of *Pathology ‡Surgery, Division of Transplantation, University of California at San Francisco, San Francisco, CA †Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY.

Insights

Donor livers with significant small droplet macrovesicular steatosis (MaS) increase rejection risk, but large droplet MaS does not. Distinguishing between MaS types is crucial for liver transplant outcomes.

Area of Science:

  • Hepatology
  • Transplantation immunology
  • Pathology

Background:

  • Current consensus on donor liver steatosis (MaS) safety uses variable definitions.
  • A reproducible scoring system for MaS subtypes is lacking.
  • Donor liver quality impacts transplant outcomes.

Purpose of the Study:

  • To determine if large or small droplet MaS is a risk factor for poor liver allograft outcomes.
  • To establish a reproducible scoring system for MaS subtypes.
  • To assess the impact of MaS on acute cellular rejection and chronic ductopenic rejection.

Main Methods:

  • Analysis of 134 donor liver biopsies from allografts transplanted between 2000-2015.
  • Defined and scored large droplet MaS (fat droplet >1/2 hepatocyte) and small droplet MaS (fat droplet <1/2 hepatocyte).
  • Reviewed electronic medical records for outcomes including rejection and patient survival.

Main Results:

  • Donor livers with ≥30% small droplet MaS showed increased risk of acute cellular rejection (HR=2.5) and bile duct loss (HR=2.4).
  • Large droplet MaS (up to 60%) was not associated with adverse outcomes.
  • Excellent inter-observer agreement was achieved for both large (κ=0.682) and small droplet MaS (κ=0.780) scoring.

Conclusions:

  • Distinguishing between small and large droplet MaS is vital for evaluating donor liver quality.
  • A reproducible scoring system for MaS can identify liver allograft recipients at increased risk for rejection.
  • Small droplet MaS, not large droplet MaS, is a significant risk factor for adverse transplant outcomes.

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...